WO2026130492 - ANTI-DLL3/B7H3 ANTIBODIES AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2026/130492
Publication Date
25.06.2026
International Application No.
PCT/CN2025/143719
International Filing Date
19.12.2025
Title **
[English]
ANTI-DLL3/B7H3 ANTIBODIES AND USES THEREOF
[French]
ANTICORPS ANTI-DLL3/B7H3 ET LEURS UTILISATIONS
Applicants **
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
Inventors
YANG, Liu
AN, Wenqian
Priority Data
PCT/CN2024/140987
20.12.2024
CN
PCT/CN2025/086885
02.04.2025
CN
PCT/CN2025/125620
30.09.2025
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2990 | |
| EPO | Filing, Examination, Granting | 28027 | |
| Japan | Filing, Examination, Granting | 3150 | |
| South Korea | Filing, Examination, Granting | 4204 | |
| USA | Filing, Examination, Granting | 14340 |
Total:
52,711
Contact Us
Abstract[English]
This disclosure provides anti-DLL3/B7H3 antibodies, antibody drug conjugates, and the uses thereof.[French]
La présente divulgation concerne des anticorps anti-DLL3/B7H3, des conjugués anticorps-médicament et leurs utilisations.